Anti-VEGF antibodies

  • US 7,375,193 B2
  • Filed: 09/29/2006
  • Issued: 05/20/2008
  • Est. Priority Date: 04/07/1997
  • Status: Expired due to Fees
First Claim
Patent Images

1. An aqueous formulation useful for inhibiting VEGF-induced angiogenesis in a subject, comprising as the active compound a humanized anti-VEGF antibody in a buffer, wherein the anti-VEGF antibody comprises a heavy chain variable domain comprising the following heavy chain complementarity determining region (CDR) amino acid sequences:

  • CDRH1 (GYTFTNYGMN;

    SEQ ID NO;

         1), CDRH2 (WINTYTGEPTYAADFKR;

    SEQ ID NO;

         2) and CDRH3 (YPHYYGSSHWYFDV;

    SEQ ID NO;

         3) and a light chain variable domain comprising the following light chain CDR amino acid sequences;

    CDRL1 (SASQDISNYLN;

    SEQ ID NO;

         4), CDRL2 (FTSSLHS;

    SEQ ID NO;

         5) and CDRL3 (QQYSTVPWT;

    SEQ ID NO;

         6).

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×